• Mechanism

  • Disease areas


Medivir’s Metallo Beta Lactamase (MBLI) program aimed at addressing the threat of resistant bacteria was out-licensed in 2017 to the AMR Centre (today INFEX Therapeutics) in England.

In 2022, INFEX has presented additional preclinical data, received QIDP-designation and communicated its intention to initiate a phase I program in 2022/23 for MET-X. In October, INFEX received patent approval for the substance in the United States. Medivir is entitled to a share of potential future revenue.